Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
December 08, 2022 07:00 ET
|
Trevena, Inc.
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster...
Trevena Regains Compliance with Nasdaq Listing Requirements
November 29, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 16, 2022 08:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces Reverse Stock Split
November 09, 2022 16:01 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
November 09, 2022 07:02 ET
|
Trevena, Inc.
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of...
Trevena Reports Third Quarter 2022 Results and Provides Business Update
November 09, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no...
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
November 07, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
October 24, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as...
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
September 07, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2022 Results and Provides Business Update
August 11, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 study for TRV045, a novel S1P receptor...